低风险对乙酰氨基酚过量后12小时与20小时乙酰半胱氨酸方案的代谢物浓度比较
本研究为NACSTOP试验的试点研究,比较低风险对乙酰氨基酚过量患者接受12小时缩短乙酰半胱氨酸方案(200 mg/kg持续4小时,50 mg/kg持续8小时)与20小时标准方案(200 mg/kg持续4小时,100 mg/kg持续16小时)后的肝损伤程度和代谢物浓度。40例患者共采集141份血样,采用液相色谱/质谱法测定对乙酰氨基酚代谢物。12小时组20小时后ALT中位数12 U/L(IQR 8.14),对照组16 U/L(IQR 11.21),差异无统计学意义(p=.46)。两组就诊时和20小时后的代谢物浓度中位数均无显著差异(p>.05)。结论提示缩短方案在低风险患者中代谢物浓度与标准方案相似,停药时可能无需进一步乙酰半胱氨酸治疗。
要点
- 低风险对乙酰氨基酚过量患者接受12小时缩短乙酰半胱氨酸方案后20小时ALT中位数12 U/L(IQR 8.14),与20小时标准方案16 U/L(IQR 11.21)无显著差异(p=.46)。
- 两组就诊时和20小时后的对乙酰氨基酚代谢物浓度中位数均无显著差异(p>.05)。
- 就诊时CYP代谢物占总代谢物百分比中位数:12小时缩短方案组2.5%,20小时对照组3.0%。
- 12小时方案为200 mg/kg持续4小时加50 mg/kg持续8小时;20小时标准方案为200 mg/kg持续4小时加100 mg/kg持续16小时。
- 作者认为,在低风险患者中12小时方案停药时可能无需进一步乙酰半胱氨酸治疗。
适用人群与场景
- 纳入NACSTOP试验的低肝毒性风险对乙酰氨基酚过量患者,接受乙酰半胱氨酸治疗。
- 另设非试验的阳性对照组,包括急性肝损伤(ALI)或肝毒性患者。
处置流程与药物剂量
- 12小时缩短方案:乙酰半胱氨酸200 mg/kg持续4小时,继以50 mg/kg持续8小时,至少治疗12小时后停药。
- 20小时标准方案:乙酰半胱氨酸200 mg/kg持续4小时,继以100 mg/kg持续16小时。
研究设计与关键结果
- 研究类型:NACSTOP集群对照试验的试点研究,40例患者共采集141份血样,采用液相色谱/质谱法测定对乙酰氨基酚代谢物。
- 主要终点:20小时乙酰半胱氨酸后ALT中位数12小时缩短方案组12 U/L(IQR 8.14)vs 20小时标准方案组16 U/L(IQR 11.21),p=.46。
- 两组就诊时和20小时后的代谢物浓度中位数均无显著差异(p>.05)。
- 就诊时CYP代谢物占总代谢物百分比中位数:12小时缩短方案组2.5% vs 20小时标准方案组3.0%。
证据类型、等级与局限
- 证据类型:集群对照试验的试点研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在低肝毒性风险的对乙酰氨基酚过量患者中,12小时缩短乙酰半胱氨酸方案停药时可能无需进一步乙酰半胱氨酸治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: To compare degree of liver injury and paracetamol metabolite concentrations after treatment with standard of care (20-h) vs. abbreviated (12-h) acetylcysteine regimens used in paracetamol overdose (NACSTOP trial).
METHODS: Timed blood samples from a cohort of subjects enrolled in the cluster-controlled NACSTOP trial evaluating a 12-h acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h) were assayed for paracetamol metabolites as a pilot study, using liquid chromatography/mass spectrometry. Control group subjects received a 20-h course of acetylcysteine (200 mg/kg over 4 h, 100 mg/kg over 16 h). The intervention group received a 12-h acetylcysteine regimen (stopped after at least 12 h of treatment). Positive control groups not in the trial with acute liver injury (ALI) or hepatotoxicity were also studied.
RESULTS: One hundred and forty-one blood samples were collected from 40 patients receiving acetylcysteine after paracetamol overdose. Median ALT after 20 h of acetylcysteine was 12 U/L (IQR 8.14) in the abbreviated regimen group, compared to the control group 16 U/L (IQR 11.21) (p = .46). There was no significant difference in median metabolite concentrations on presentation and after 20 h of acetylcysteine between these two groups (p > .05). Presentation median sum CYP-metabolite/total metabolite percentages were 2.5 and 3.0 in the abbreviated and control NACSTOP groups, respectively.
CONCLUSIONS: An abbreviated 12-h acetylcysteine regimen for paracetamol overdose used in the NACSTOP trial had similar circulating metabolite concentrations compared to a 20-h regimen in selected subjects with low risk of hepatotoxicity. This suggests that further acetylcysteine may not be needed in the abbreviated group at time of cessation.
参考来源
- Wong A, Homer N, Dear JW, et al. Paracetamol metabolite concentrations following low risk overdose treated with an abbreviated 12-h versus 20-h acetylcysteine infusion. Clin Toxicol (Phila). 2018. PMID: 30453788. doi:10.1080/15563650.2018.1517881
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。